<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00814177</url>
  </required_header>
  <id_info>
    <org_study_id>HRC060425</org_study_id>
    <nct_id>NCT00814177</nct_id>
  </id_info>
  <brief_title>Prothrombin Times Outside the Therapeutic Range in Otherwise Stable Patients</brief_title>
  <acronym>FORESPEAK-0</acronym>
  <official_title>Management of Prothrombin Times Outside the Therapeutic Range in Patients on Warfarin and With Otherwise Stable Levels</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hamilton Health Sciences Corporation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>McMaster University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Warfarin is very effective for the prevention of blood clots (thrombosis). A test of
      coagulation, the prothrombin time (PT) is used to monitor the effect. The PT response to
      warfarin can fluctuate as a result of interactions with a large number of other drugs, food
      or herbal agents as well as for no apparent reason. Thus, frequent monitoring of the PT and
      dose adjustments according to the results are required. One third of our patients remain on
      the same maintenance dose over 6 months. However, also these patients sometimes have a PT
      result moderately outside the therapeutic range without any obvious explanation. Too short
      PTs may be due to missed dose(s) or more dark green vegetables in the diet. Too long PTs may
      be due to a course of antibiotic therapy or less dark green vegetables. Laboratory errors may
      also occur and can cause deviations in any direction. Most likely, unnoticed fluctuations in
      the PT occur as well between the time points of monitoring.

      There are no guidelines on how to manage the treatment in this situation but there are some
      typical &quot;behaviours&quot;.

      Behavior A: Some physicians simply let the patient continue with the same dose. &quot;It is
      extremely unlikely that the very temporary dose adjustment has any effect on the PT result 4
      weeks later and this is a &quot;cosmetic procedure&quot;.&quot; Behavior B: Others recommend the patients to
      take ½ - 1 additional dose in case of short PT and to skip a dose or take half dose in case
      of long PT, and thereafter to continue with the usual dose. &quot;The investigators need to
      quickly correct the temporary aberration in order to avoid thrombotic or bleeding
      complications the next few days.

      This may seem like an issue of no importance. The investigators are however performing a
      series of studies to evaluate if these stable patients can be managed with blood tests less
      often than every 4 weeks. For that purpose it is important to know how often and why aberrant
      results occur, the implication and to what extent they can be ignored.

      The investigators hypothesis is that in patients with very stable PT-results and unchanged
      dose for 3 months, should continue with exactly the same maintenance dose, even when the
      result unexpectedly is slightly above or below the therapeutic range. The investigators
      believe that most of these occasional PT-results outside the therapeutic range are due to
      laboratory errors, perhaps missed doses by the patient or temporary change in diet or
      medications.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Setting:

      Thrombosis Service at HHS - General Hospital. This center monitors the warfarin treatment for
      1300 patients in the region. These patient regularly go to a laboratory where they live. Test
      results (INR-results) are faxed to the Thrombosis Service, which calls the patient the same
      day to inform them of the results, how to continue dosing the warfarin and when to go for the
      following blood test.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2006</start_date>
  <completion_date type="Actual">April 2009</completion_date>
  <primary_completion_date type="Actual">January 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Patients With Prothrombin Time Results Within the Therapeutic Range After 2 Weeks</measure>
    <time_frame>2 weeks</time_frame>
    <description>The number of patients with &quot;follow-up INRs&quot; within the therapeutic range was compared for patients with a single dose skipped/reduced/added versus patients with no change of dose.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">160</enrollment>
  <condition>Atrial Fibrillation</condition>
  <condition>Venous Thromboembolism</condition>
  <condition>Ischemic Stroke</condition>
  <condition>Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>No change</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intervention Drug warfarin no change in the dose is performed</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Change</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intervention Drug Warfarin One dose increased if subtherapeutic level; one dose deleted or reduced if supratherapeutic level</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>warfarin</intervention_name>
    <description>No change: Continue without any change in spite of prothrombin time outside the therapeutic range.</description>
    <arm_group_label>No change</arm_group_label>
    <other_name>Coumadin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>warfarin</intervention_name>
    <description>Change: Increase one dose in case prothrombin time is below the therapeutic range; delete or reduce one dose in case prothrombin time is above the therapeutic range.</description>
    <arm_group_label>Change</arm_group_label>
    <other_name>Coumadin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients on long-term warfarin (for prophylaxis of arterial embolism in patients with
             atrial fibrillation or mechanical heart valve replacement, or secondary prophylaxis
             after VTE) with a target INR of 2.0-3.0 or 2.5-3.5,

          2. Anticoagulant therapy managed by the clinic (HHS - General Hospital) for at least 3
             months prior to enrolment, and

          3. Maintenance dose of warfarin unchanged for the previous 3 months or longer.

          4. The INR result is outside the therapeutic range as follows:

        For those with target 2.0-3.0: Either an INR of 1.5-1.9 or an INR of 3.1-4.4. For those
        with target 2.5-3.5: Either an INR of 1.5-2.4 or an INR of 3.6-4.4.

        Exclusion Criteria:

          1. Age &lt;18 years,

          2. Long-term (&gt;1 week) change in any other medication

          3. Long-term (&gt;1 week) change in diet, especially regarding green vegetables.

          4. Attending physician believes the patient is not suitable for the study (e.g.
             psychiatric disorder, history of non-compliance),

          5. Failure to obtain telephone consent.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sam Schulman, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>McMaster University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Thrombosis Service, HHS-General Hospital</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8L 2X2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <results_reference>
    <citation>Schulman S, Melinyshyn A, Ennis D, Rudd-Scott L. Single-dose adjustment versus no adjustment of warfarin in stably anticoagulated patients with an occasional international normalized ratio (INR) out of range. Thromb Res. 2010 May;125(5):393-7. doi: 10.1016/j.thromres.2009.07.006. Epub 2009 Jul 29.</citation>
    <PMID>19640572</PMID>
  </results_reference>
  <verification_date>July 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 23, 2008</study_first_submitted>
  <study_first_submitted_qc>December 23, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 24, 2008</study_first_posted>
  <results_first_submitted>October 7, 2009</results_first_submitted>
  <results_first_submitted_qc>October 7, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 25, 2009</results_first_posted>
  <last_update_submitted>July 24, 2012</last_update_submitted>
  <last_update_submitted_qc>July 24, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 1, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>McMaster University</investigator_affiliation>
    <investigator_full_name>Sam Schulman</investigator_full_name>
    <investigator_title>Professor, MD</investigator_title>
  </responsible_party>
  <keyword>warfarin</keyword>
  <keyword>dosing</keyword>
  <keyword>prothrombin time</keyword>
  <keyword>Heart valve prosthesis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Thromboembolism</mesh_term>
    <mesh_term>Venous Thromboembolism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Warfarin</mesh_term>
    <mesh_term>Thrombin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>160 patients were randomized at a single center during the period July 2006 – August 2008</recruitment_details>
      <pre_assignment_details>The study was planned for the sample size of 326 but due to competing studies, testing new dosing algorithms, the inclusion rate was much lower than expected.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>No Change</title>
          <description>Intervention Drug warfarin no change in the dose is performed</description>
        </group>
        <group group_id="P2">
          <title>Change</title>
          <description>Intervention Drug Warfarin One dose increased if subtherapeutic level; one dose deleted or reduced if supratherapeutic level</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="80"/>
                <participants group_id="P2" count="80"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="80"/>
                <participants group_id="P2" count="80"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>No Change</title>
          <description>Intervention Drug warfarin no change in the dose is performed</description>
        </group>
        <group group_id="B2">
          <title>Change</title>
          <description>Intervention Drug Warfarin One dose increased if subtherapeutic level; one dose deleted or reduced if supratherapeutic level</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="80"/>
            <count group_id="B2" value="80"/>
            <count group_id="B3" value="160"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59"/>
                    <measurement group_id="B2" value="47"/>
                    <measurement group_id="B3" value="106"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="69.6" spread="11.4"/>
                    <measurement group_id="B2" value="67.1" spread="13.8"/>
                    <measurement group_id="B3" value="68.4" spread="12.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="34"/>
                    <measurement group_id="B3" value="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49"/>
                    <measurement group_id="B2" value="46"/>
                    <measurement group_id="B3" value="95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="80"/>
                    <measurement group_id="B2" value="80"/>
                    <measurement group_id="B3" value="160"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Patients With Prothrombin Time Results Within the Therapeutic Range After 2 Weeks</title>
        <description>The number of patients with &quot;follow-up INRs&quot; within the therapeutic range was compared for patients with a single dose skipped/reduced/added versus patients with no change of dose.</description>
        <time_frame>2 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>No Change</title>
            <description>Intervention Drug warfarin no change in the dose is performed</description>
          </group>
          <group group_id="O2">
            <title>Change</title>
            <description>Intervention Drug Warfarin One dose increased if subtherapeutic level; one dose deleted or reduced if supratherapeutic level</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Prothrombin Time Results Within the Therapeutic Range After 2 Weeks</title>
          <description>The number of patients with &quot;follow-up INRs&quot; within the therapeutic range was compared for patients with a single dose skipped/reduced/added versus patients with no change of dose.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="80"/>
                <count group_id="O2" value="80"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48"/>
                    <measurement group_id="O2" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>2 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>No Change</title>
          <description>Intervention Drug warfarin no change in the dose is performed</description>
        </group>
        <group group_id="E2">
          <title>Change</title>
          <description>Intervention Drug Warfarin One dose increased if subtherapeutic level; one dose deleted or reduced if supratherapeutic level</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>ventricular tachycardia</sub_title>
                <description>triggered by implanted defibrillator malfunction</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>food poisoning</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>bleeding from penis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Sam Schulman, MD</name_or_title>
      <organization>McMaster University</organization>
      <phone>1-905-5270271 ext 44479</phone>
      <email>schulms@mcmaster.ca</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

